CAR-TCR Summit Europe
In-Person Event
Feb 20 - 22, 2018
London, England, GB
OVERVIEW
Chimeric antigen receptor (CAR) - T cell receptor (TCR) Summit Europe is organized by Hanson Wade and will be held during Feb 20 - 22, 2018 at DoubleTree by Hilton Hotel London - Docklands Riverside, London, England, United Kingdom.
This conference is the leading end-to-end summit focused on delivering safe, effective and commercially successful CAR and TCR cell therapies globally. With the first CAR-T approved and the next poised to receive approval from the FDA and EMA by the end of 2017, CAR-T therapies aren't going anywhere and are set to become mainstream frontline cancer treatments.
As we see success, there are still two key areas even for the leaders to address: European regulations and global distribution. Alongside this, addressing the challenges with improving the underwhelming performance of CAR-TCR therapies in solid tumor indications are more important now than ever before. CAR-TCR Summit Europe brings you access to the leaders in this field and the hub of companies creating novel innovations in Europe. We set the stage for visionary leaders to transform the commercial and clinical delivery of cancer therapeutics.
Gain exclusive insight on current clinical programs and case studies on the next wave of CAR-TCR candidates from those pioneering in this field.
Focusing on navigating the regulatory minefield and ensuring successful global distribution and delivery of CAR-T and TCR therapies, CAR-TCR Summit Europe is your opportunity to network, interact and learn at the only end-to-end meeting that fosters the transformation of leading science to commercial therapies.
Speakers: Jian Irish, SVP, Supply Chain, Kite Pharma, Lothar Germeroth, SVP, Managing Director, Juno Therapeutics, Isaac Ciechanover, CEO, Atara Biotherapeutics, Jens Hasskarl, Senior Director, Medical, Clinical Research And Development, Celgene, John Maher, CSO, Leucid Bio, Thierry Wurch, Director. Immuno-Oncology External Research And Innovation, Servier, Helen Tayton-Martin, CBO, Adaptimmune, Representative to be confirmed, Cellectis, Dolores Schendel, CEO, Medigene, Elisa Kieback, CEO, T-Knife, Michael Leek, CEO, TC Biopharm, Oezlem Anak, Senior Global Clinical Programme Head, Cell And Gene Therapies, Novartis, Martina Schussler-Lenz, Chair CAT, EMA, Miltenyi Biotec, ACD.
Additional details will be posted as soon as they are available.
This conference is the leading end-to-end summit focused on delivering safe, effective and commercially successful CAR and TCR cell therapies globally. With the first CAR-T approved and the next poised to receive approval from the FDA and EMA by the end of 2017, CAR-T therapies aren't going anywhere and are set to become mainstream frontline cancer treatments.
As we see success, there are still two key areas even for the leaders to address: European regulations and global distribution. Alongside this, addressing the challenges with improving the underwhelming performance of CAR-TCR therapies in solid tumor indications are more important now than ever before. CAR-TCR Summit Europe brings you access to the leaders in this field and the hub of companies creating novel innovations in Europe. We set the stage for visionary leaders to transform the commercial and clinical delivery of cancer therapeutics.
Gain exclusive insight on current clinical programs and case studies on the next wave of CAR-TCR candidates from those pioneering in this field.
Focusing on navigating the regulatory minefield and ensuring successful global distribution and delivery of CAR-T and TCR therapies, CAR-TCR Summit Europe is your opportunity to network, interact and learn at the only end-to-end meeting that fosters the transformation of leading science to commercial therapies.
Speakers: Jian Irish, SVP, Supply Chain, Kite Pharma, Lothar Germeroth, SVP, Managing Director, Juno Therapeutics, Isaac Ciechanover, CEO, Atara Biotherapeutics, Jens Hasskarl, Senior Director, Medical, Clinical Research And Development, Celgene, John Maher, CSO, Leucid Bio, Thierry Wurch, Director. Immuno-Oncology External Research And Innovation, Servier, Helen Tayton-Martin, CBO, Adaptimmune, Representative to be confirmed, Cellectis, Dolores Schendel, CEO, Medigene, Elisa Kieback, CEO, T-Knife, Michael Leek, CEO, TC Biopharm, Oezlem Anak, Senior Global Clinical Programme Head, Cell And Gene Therapies, Novartis, Martina Schussler-Lenz, Chair CAT, EMA, Miltenyi Biotec, ACD.
Additional details will be posted as soon as they are available.
KEY DATES
20 Feb, 2018
Event Start Date
22 Feb, 2018
Event End Date
SPECIALITIES
Immunology and MicrobiologyClinical GeneticsSUGGESTED HOTELS
CONFERENCE VENUE
DoubleTree by Hilton Hotel London - Docklands RiversideRELATED CONFERENCES & LIVE WEBINARS
Quick Links